Kura Oncology Stock EBITDA
| KURA Stock | USD 10.06 5.85 36.77% |
Kura Oncology fundamentals help investors to digest information that contributes to Kura Oncology's financial success or failures. It also enables traders to predict the movement of Kura Stock. The fundamental analysis module provides a way to measure Kura Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kura Oncology stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -165 M | -156.7 M |
Kura | EBITDA |
Kura Oncology Company EBITDA Analysis
Kura Oncology's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Kura Oncology EBITDA | (164.96 M) |
Most of Kura Oncology's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kura Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Kura EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Kura Oncology is extremely important. It helps to project a fair market value of Kura Stock properly, considering its historical fundamentals such as EBITDA. Since Kura Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kura Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kura Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Kura Ebitda
Ebitda |
|
According to the company disclosure, Kura Oncology reported earnings before interest,tax, depreciation and amortization of (164.96 Million). This is 118.8% lower than that of the Biotechnology sector and 264.7% lower than that of the Health Care industry. The ebitda for all United States stocks is 104.23% higher than that of the company.
Kura EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kura Oncology's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics of similar companies.Kura Oncology is currently under evaluation in ebitda category among its peers.
Kura Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kura Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kura Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Kura Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Kura Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kura Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kura Oncology's value.| Shares | Armistice Capital, Llc | 2024-06-30 | 2.4 M | Deep Track Capital, Lp | 2024-09-30 | 2 M | Foresite Capital Management Iv, Llc | 2024-06-30 | 1.8 M | Artal Group S A | 2024-06-30 | 1.8 M | Geode Capital Management, Llc | 2024-06-30 | 1.7 M | Commodore Capital Lp | 2024-06-30 | 1.6 M | Franklin Resources Inc | 2024-06-30 | 1.6 M | Tcg Crossover Management, Llc | 2024-09-30 | 1.4 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.1 M | Suvretta Capital Management, Llc | 2024-06-30 | 7.1 M | Blackrock Inc | 2024-06-30 | 7 M |
Kura Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 343.64 M | ||||
| Shares Outstanding | 77.76 M | ||||
| Shares Owned By Insiders | 1.05 % | ||||
| Shares Owned By Institutions | 98.95 % | ||||
| Number Of Shares Shorted | 10.8 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 1.85 X | ||||
| EBITDA | (164.96 M) | ||||
| Net Income | (152.63 M) | ||||
| Cash And Equivalents | 450.26 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 17.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.73 X | ||||
| Book Value Per Share | 5.45 X | ||||
| Cash Flow From Operations | (124.82 M) | ||||
| Short Ratio | 18.69 X | ||||
| Earnings Per Share | (2.35) X | ||||
| Target Price | 29.07 | ||||
| Number Of Employees | 142 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 782.3 M | ||||
| Total Asset | 448.94 M | ||||
| Retained Earnings | (721.44 M) | ||||
| Working Capital | 397.22 M | ||||
| Current Asset | 86.87 M | ||||
| Current Liabilities | 5.05 M | ||||
| Net Asset | 448.94 M |
About Kura Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Kura Oncology Piotroski F Score and Kura Oncology Altman Z Score analysis. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.35) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.